Key facts
- Xilis’s last known valuation is $57.0M (Apr 2025).
- It has raised $114.7M; the latest was Later Stage VC ($19.4M) in Apr 2025.
- Notable investors include Mubadala Investment Company, GV, Liquid 2 Ventures, 8VC, Felicis — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Xilis
- ·The full record, as it builds
Funding rounds
No funding rounds for Xilis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xilis
Developer of micro-organ sphere technology designed to guide precision therapy for cancer patients and accelerate drug discovery. The company's platform enables rapid diagnostics, personalized drug screening, and scalable patient-derived models for high-throughput drug discovery, enabling physicians and pharmaceutical companies to develop tailored treatments for patients by conducting drug screening at a lower cost.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2019
- Employees
- 65
- Website
- xilis.com/
- Ownership
- Privately Held (backing)
Xilis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xilis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xilis in its N-PORT filings yet. We sweep new filings monthly.